Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types
Provided By PR Newswire
Last update: Apr 19, 2022
Proposed ~$250 million all-cash acquisition strengthens Regeneron's portfolio of diverse and combinable immuno-oncology candidates
Lead investigational asset vidutolimod is a potential best-in-class TLR9 agonist, with demonstrated clinical responses observed in PD-1 refractory melanoma as monotherapy
Read more at prnewswire.com700.33
+4.31 (+0.62%)
Find more stocks in the Stock Screener
REGN Latest News and Analysis
12 days ago - ChartmillDiscover the top S&P500 movers in Wednesday's pre-market session.Get insights into the top gainers and losers in the S&P500 index of Wednesday's pre-market session.
19 days ago - ChartmillUncover the latest developments among S&P500 stocks in today's session.Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.
20 days ago - ChartmillDiscover which S&P500 stocks are making waves on Tuesday.Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Tuesday as we examine the latest happenings in today's session.
